

Practitioner's Docket No. MWH-0031US

PATENT

118/A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Liggett, Stephen B.

Application No.: To be assigned
Filed: September 12, 2001

Group No.: To be assigned
Examiner: To be assigned

For: Variation in Drug Response Related to Polymorphisms in the B₂-Adrenergic Receptor

Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT TO SPECIFICATION
(37 C.F.R. 1.121 and M.P.E.P. 714.09)

This paper is filed to amend typographical errors found in the specification.

IN THE SPECIFICATION

Please amend the following:

Page 1, line 28: rewrite "490" as -- 491 --


Page 9, line 8: rewrite "+490" as -- +491 --

NE Page 10, line 8: rewrite "+490PS" as -- +491PS --

REMARKS

Applicants have identified three typographical errors in the specification in which the polymorphic site discovered by the Applicants was erroneously typed as "490" and not "491". Support for these amendments can be found on page 1, line 27 to page 2, line 1 as well as on page 7, line 26 and other parts of the specification. Applicants respectfully submit that it would be obvious, to one skilled in the art that Applicants had intended to mean that a variation of C or T at a position of +491, and not +490, results in an amino acid variation of isoleucine or threonine at amino acid 164. It is respectfully submitted that this amendment does not introduce new matter and its entry is respectfully requested. Should any questions arise, or if Applicant or Applicant's Agent can facilitate examination of this Application, please contact the undersigned Agent at the phone number below.

Respectfully Submitted,


Gisela M. Field
Genaissance Pharmaceuticals, Inc.
Five Science Park
New Haven, CT 06511

Reg. No. 47,562
Tel. No. 203-786-3473